Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
Eligible age
2+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This project aims to address invasive fungal infections in patients, by precision dosing of voriconazole based on CYP2C19 genotype testing with Bayesian dose-forecasting dosing software to develop patient-centric and maximally effective dosing regimens. This study investigates if voriconazole increases the proportion of patients achieving therapeutic exposure at day 8 of dosing compared with standard care; and will assess factors that influence the implementation of genotype testing and dosing software in the healthcare system, including fidelity, feasibility, acceptability and cost-effectiveness. It will recruit at least 104 kids and adults in a parallel-group randomised clinical trial. A hybrid feasibility sub-study will assess the scalability of genotype-directed dosing to ensure sustainable integration of the interventions into the clinical workflow. A health economic sub-study will evaluate the costs, health outcomes and cost-effectiveness of genotype-directed testing compared to standard care.
Sponsor: The University of Queensland
You may qualify if…
- ✓ Age ≥ 2 years.
- ✓ Written informed consent obtained.
- ✓ Decision to prescribe voriconazole.
- ✓ Admitted to a trial site, or sufficient outpatient follow-up appointments are feasible
You may not qualify if…
- ✕ Post-allogeneic haematopoietic stem cell transplant (HCT) patient, without access to pre HCT DNA
- ✕ Death is likely imminent within 7 days.
- ✕ Previously randomised to this trial
Where it's recruiting
Seattle
Source: ClinicalTrials.gov · NCT06510699 · last updated 2026-04-16